MicroRNA and Protein Cargos of Human Limbal Epithelial Cell-Derived Exosomes and Their Regulatory Roles in Limbal Stromal Cells of Diabetic and Non-Diabetic Corneas.
RNA-seq
cellular crosstalk
diabetic cornea
exosome
extracellular vesicles
limbal epithelial cells
limbal stem cells
mesenchymal stem cells
miRNA
proteomics
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
25 Oct 2023
25 Oct 2023
Historique:
received:
13
09
2023
revised:
08
10
2023
accepted:
18
10
2023
medline:
13
11
2023
pubmed:
10
11
2023
entrez:
10
11
2023
Statut:
epublish
Résumé
Epithelial and stromal/mesenchymal limbal stem cells contribute to corneal homeostasis and cell renewal. Extracellular vesicles (EVs), including exosomes (Exos), can be paracrine mediators of intercellular communication. Previously, we described cargos and regulatory roles of limbal stromal cell (LSC)-derived Exos in non-diabetic (N) and diabetic (DM) limbal epithelial cells (LECs). Presently, we quantify the miRNA and proteome profiles of human LEC-derived Exos and their regulatory roles in N- and DM-LSC. We revealed some miRNA and protein differences in DM vs. N-LEC-derived Exos' cargos, including proteins involved in Exo biogenesis and packaging that may affect Exo production and ultimately cellular crosstalk and corneal function. Treatment by N-Exos, but not by DM-Exos, enhanced wound healing in cultured N-LSCs and increased proliferation rates in N and DM LSCs vs. corresponding untreated (control) cells. N-Exos-treated LSCs reduced the keratocyte markers ALDH3A1 and lumican and increased the MSC markers CD73, CD90, and CD105 vs. control LSCs. These being opposite to the changes quantified in wounded LSCs. Overall, N-LEC Exos have a more pronounced effect on LSC wound healing, proliferation, and stem cell marker expression than DM-LEC Exos. This suggests that regulatory miRNA and protein cargo differences in DM- vs. N-LEC-derived Exos could contribute to the disease state.
Identifiants
pubmed: 37947602
pii: cells12212524
doi: 10.3390/cells12212524
pmc: PMC10649916
pii:
doi:
Substances chimiques
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NEI NIH HHS
ID : R01 EY029829
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY013431
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY025377
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY031377
Pays : United States
Organisme : NEI NIH HHS
ID : R01 grants EY025377, EY029829 (MS), EY013431, EY031377 (AVL)
Pays : United States
Références
PLoS One. 2014 Dec 09;9(12):e114692
pubmed: 25490205
Mol Aspects Med. 2018 Apr;60:81-91
pubmed: 29175307
Physiol Rev. 2011 Jan;91(1):119-49
pubmed: 21248164
Stem Cells. 2005 Oct;23(9):1266-75
pubmed: 16051989
Nat Biotechnol. 2014 Mar;32(3):219-23
pubmed: 24727770
Stem Cells Int. 2017;2017:9275248
pubmed: 29213290
J Proteomics. 2015 Nov 3;129:108-120
pubmed: 26381204
Cells. 2022 Oct 14;11(20):
pubmed: 36291096
Chin Med J (Engl). 2018 Mar 20;131(6):704-712
pubmed: 29521294
Stem Cells. 2017 Oct;35(10):2105-2114
pubmed: 28748596
Proteomics Clin Appl. 2015 Aug;9(7-8):745-54
pubmed: 25631240
Nat Methods. 2016 Sep;13(9):777-83
pubmed: 27479329
Genome Biol. 2009;10(3):R25
pubmed: 19261174
Crit Rev Clin Lab Sci. 2016;53(2):121-31
pubmed: 26479834
Sci Rep. 2018 Jul 17;8(1):10813
pubmed: 30018314
Sci Rep. 2018 Oct 11;8(1):15173
pubmed: 30310159
Trends Cell Biol. 2009 Feb;19(2):43-51
pubmed: 19144520
BMC Genomics. 2012 Aug 01;13:357
pubmed: 22849433
Front Pharmacol. 2021 Aug 19;12:684712
pubmed: 34489693
Nat Methods. 2015 Mar;12(3):258-64, 7 p following 264
pubmed: 25599550
J Am Soc Mass Spectrom. 2020 Jul 1;31(7):1410-1421
pubmed: 32463229
Anat Rec (Hoboken). 2020 Jun;303(6):1727-1734
pubmed: 31136100
Stem Cell Res. 2010 Nov;5(3):188-200
pubmed: 20813601
Stem Cells. 2012 Jun;30(6):1059-63
pubmed: 22489057
Exp Eye Res. 2021 Mar;204:108455
pubmed: 33485845
Theranostics. 2022 Jan 1;12(3):1342-1372
pubmed: 35154494
J Proteome Res. 2008 Jan;7(1):293-9
pubmed: 17902638
Prog Retin Eye Res. 2017 Jul;59:158-177
pubmed: 28465248
Int J Biol Sci. 2021 Jan 1;17(1):163-177
pubmed: 33390841
Cancer Metastasis Rev. 2013 Dec;32(3-4):623-42
pubmed: 23709120
Front Oncol. 2021 Aug 31;11:728393
pubmed: 34532291
Exp Eye Res. 2009 Aug;89(2):133-9
pubmed: 19285070
Wound Repair Regen. 2011 Jan-Feb;19(1):98-106
pubmed: 21134038
Int J Mol Sci. 2022 Oct 13;23(20):
pubmed: 36293057
PLoS One. 2018 Apr 24;13(4):e0195969
pubmed: 29689087
Invest Ophthalmol Vis Sci. 2018 Oct 1;59(12):5194-5200
pubmed: 30372747
Cells. 2020 Sep 26;9(10):
pubmed: 32993109
Regen Med. 2011 Nov;6(6):767-82
pubmed: 22050528
Sci Rep. 2017 Feb 06;7:40548
pubmed: 28165027
Methods Mol Biol. 2016;1364:105-25
pubmed: 26472446
Front Immunol. 2021 Nov 30;12:765890
pubmed: 34917084
Science. 2008 Feb 29;319(5867):1191-2
pubmed: 18309064
PLoS One. 2014 Apr 08;9(4):e94283
pubmed: 24714106
Stem Cells. 2011 Nov;29(11):1874-85
pubmed: 21948620
Invest Ophthalmol Vis Sci. 2012 Nov 01;53(12):7476-83
pubmed: 23049092
FASEB J. 2005 Aug;19(10):1371-3
pubmed: 15901670
Development. 2016 Jun 15;143(12):2160-71
pubmed: 27122169
Life Sci. 2020 Nov 15;261:118311
pubmed: 32861793
Nat Cell Biol. 2007 Jun;9(6):654-9
pubmed: 17486113
Cancer Manag Res. 2019 Dec 10;11:10327-10335
pubmed: 31849522
Vision Res. 2017 Oct;139:138-152
pubmed: 28404521
Ocul Surf. 2016 Jul;14(3):322-30
pubmed: 27151422
Invest Ophthalmol Vis Sci. 2012 Aug 03;53(9):5109-16
pubmed: 22736610
Prog Retin Eye Res. 2015 Sep;48:203-25
pubmed: 25916944
Ocul Surf. 2016 Apr;14(2):113-20
pubmed: 26804252
Biomolecules. 2018 Sep 14;8(3):
pubmed: 30223513
Ocul Surf. 2021 Jan;19:290-306
pubmed: 33127599
Invest Ophthalmol Vis Sci. 2019 Feb 1;60(2):650-660
pubmed: 30785991
Int Ophthalmol Clin. 1998 Spring;38(2):19-36
pubmed: 9604736
Exp Eye Res. 2020 Sep;198:108094
pubmed: 32697979
Int J Mol Sci. 2022 Apr 14;23(8):
pubmed: 35457149
PLoS One. 2013 Dec 20;8(12):e84425
pubmed: 24376808
Proteomics. 2013 Jan;13(1):22-4
pubmed: 23148064
Int Ophthalmol Clin. 2010 Summer;50(3):25-34
pubmed: 20611015
Invest Ophthalmol Vis Sci. 1983 Oct;24(10):1442-3
pubmed: 6618809
Prog Retin Eye Res. 2015 Nov;49:17-45
pubmed: 26197361
Ageing Res Rev. 2023 Mar;85:101858
pubmed: 36669689
Stem Cell Res Ther. 2015 Jul 01;6:127
pubmed: 26129847
Nat Methods. 2011 May;8(5):430-5
pubmed: 21423193
Nucleic Acids Res. 2022 Jan 7;50(D1):D543-D552
pubmed: 34723319
Sci Rep. 2017 Jun 14;7(1):3448
pubmed: 28615632
Annu Rev Cell Dev Biol. 2014;30:255-89
pubmed: 25288114
Cell. 2017 Oct 5;171(2):372-384.e12
pubmed: 28942920
Prog Retin Eye Res. 2022 Nov;91:101090
pubmed: 35649962
Commun Biol. 2021 Mar 29;4(1):427
pubmed: 33782502
Invest Ophthalmol Vis Sci. 2014 Oct 21;55(11):7583-8
pubmed: 25335980
Sci Rep. 2017 Oct 17;7(1):13321
pubmed: 29042658
J Exp Clin Cancer Res. 2017 Aug 1;36(1):100
pubmed: 28764788
Cell Mol Life Sci. 2011 Aug;68(16):2667-88
pubmed: 21560073
Invest Ophthalmol Vis Sci. 2023 Sep 1;64(12):42
pubmed: 37768272
Stem Cells. 2015 Jul;33(7):2158-68
pubmed: 24964196
Microrna. 2016;5(1):57-65
pubmed: 27280801
Regen Med. 2011 Jul;6(4):481-92
pubmed: 21749206
Nat Commun. 2011;2:282
pubmed: 21505438
J Biol Chem. 2008 Nov 21;283(47):32621-7
pubmed: 18819914